"Osteoprotegerin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A secreted member of the TNF receptor superfamily that negatively regulates osteoclastogenesis. It is a soluble decoy receptor of RANK LIGAND that inhibits both CELL DIFFERENTIATION and function of OSTEOCLASTS by inhibiting the interaction between RANK LIGAND and RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B.
| Descriptor ID |
D053244
|
| MeSH Number(s) |
D12.776.543.750.705.852.760.949.249
|
| Concept/Terms |
Osteoprotegerin- Osteoprotegerin
- Osteoclastogenesis Inhibitory Factor
- Receptors, Tumor Necrosis Factor, Member 11b
- Follicular Dendritic Cell-Derived Receptor-1
- Follicular Dendritic Cell Derived Receptor 1
- Tumor Necrosis Factor Receptor Superfamily, Member 11b
- FDCR-1 Protein
- FDCR 1 Protein
- OCIF Protein
- Tumor Necrosis Factor Receptor 11b
|
Below are MeSH descriptors whose meaning is more general than "Osteoprotegerin".
Below are MeSH descriptors whose meaning is more specific than "Osteoprotegerin".
This graph shows the total number of publications written about "Osteoprotegerin" by people in this website by year, and whether "Osteoprotegerin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2008 | 1 | 2 | 3 |
| 2009 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 6 | 3 | 9 |
| 2018 | 7 | 4 | 11 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Osteoprotegerin" by people in Profiles.
-
Osteoprotegerin and Osteopontin Serum Levels are Associated with Vascular Function and Inflammation in Coronary Artery Disease Patients. Curr Vasc Pharmacol. 2020; 18(5):523-530.
-
Alterations of Inflammatory and Matrix Production Indices in Celiac Disease With Low Bone Mass on Long-term Gluten-free Diet. J Clin Gastroenterol. 2019 07; 53(6):e221-e226.
-
Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial. Blood Adv. 2018 11 13; 2(21):2837-2847.
-
Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort. BMC Cancer. 2018 Oct 22; 18(1):1010.
-
Osteoprotegerin and Cardiovascular Events in High-Risk Populations: Meta-Analysis of 19 Prospective Studies Involving 27 450 Participants. J Am Heart Assoc. 2018 08 21; 7(16):e009012.
-
Impaired bone matrix glycoprotein pattern is associated with increased cardio-metabolic risk profile in patients with type 2 diabetes mellitus. J Endocrinol Invest. 2019 May; 42(5):513-520.
-
Dysregulation of the RANKL/RANK/OPG axis in thalassemia intermedia patients. BMC Res Notes. 2018 Jul 31; 11(1):534.
-
Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis. BMC Nephrol. 2018 07 11; 19(1):172.
-
Redundant modulatory effects of proinflammatory cytokines in human osteoblastic cells in vitro. Clin Exp Rheumatol. 2018 Nov-Dec; 36(6):959-969.
-
In silico estrogen-like activity and in vivo osteoclastogenesis inhibitory effect of Cicer arietinum extract. Cell Mol Biol (Noisy-le-grand). 2018 Apr 30; 64(5):29-39.